Immune directed therapy for ovarian carcinoma

Current Opinion in Obstetrics and Gynecology

Volumn 11, Issue 1, 1999, Pages 29-34

  Vanderkwaak, Timothy J ^a   Alvarez, Ronald D ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIBODY CONJUGATE; CISPLATIN; COMPLEMENT; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN M; INDIUM 111; INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; INTERLEUKIN 6; IODINE 131; LEAD 212; LUTETIUM; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY B.72.3; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; ONCOPROTEIN; PACLITAXEL; RHENIUM 186; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; VACCINE; YTTRIUM 90;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; FEMALE; GENE TRANSFER; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYMPHOKINE ACTIVATED KILLER CELL; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SUBCUTANEOUS DRUG ADMINISTRATION;

FEMALE; HUMANS; IMMUNOTHERAPY; OVARIAN NEOPLASMS;

EID: 0033054823     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199901000-00006     Document Type: Article

References (38)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics, 1998. Cancer J Clin 1998; 48.6-29.
2. Juweid M, Swayne LC, Sharkey RM, Dunn R, Rubin AD, Herskovic T, Goldenberg DM. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with lodine-131-labeled murine and humanized MN-14 anticarcinoembyonic antigen monoclonal antibodies Gynecol Oncol 1997; 3:259-271
3. Drebin JA, Link VC, Stern DF, Wienberg RA, Greene MI. Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 1985; 41:697-706.
4. Drebin JA, Link VC, Greene MI. Monoclonal antibodies reactive with distinct domains of the new oncogene-encoded p185 molecule exert synergistic antitumor effects in vivo. Oncogene 1988; 2:273-277.
5. Hancock MC, Langten BC, Chan T, Toy P, Monahan JJ, Mischak RP, Shawver LK. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-Diamminedichloroplatinum against human breast and ovarian tumor cell lines. Cancer Res 1991; 51:4575-4580.
6. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, et al. Efficacy and safety of Herceptin (humanized anti-HER2 antibody) as a single agent in 22 women with HER2 overexpression who relapsed following chemotherapy for metastatic cancer [abstract]. Proc ASCO 1998; 17:97a.
7. Slamon D, Leyland-Jones B, Shak S, Paton V, Bajamonde A, Fleming T, et al. Addition of Herceptin to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: a randomized, multinational controlled phase III trial [abstract]. Proc ASCO 1998; 17:98a.
8. McNeil C Herceptin raises its sights beyond advanced breast cancer. J Natl Cancer Inst 1998; 90:882-883.
9. Molthoff CFM, Prinssen HM, Kenemans P, van Hof AC, den Hollander W, • Verheijen RHM. Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I study. Cancer 1997; 80 suppl:12.2712-2720. This antibody has good targeting properties to ovarian carcinomas and reduced immunogenicity, suggesting that it may be a good candidate for clinical application
10. Schmolling J, Reinsberg J, Wagner U, Krebs D. Anti-TAG-72 antibody B72.3-immunological and clinical effects in ovarian carcinoma. Hybridoma 1997; 16:53-58.
11. Alvarez RD, Partridge EE, Khazaeli MB, Plott G, Austin M, Kilgore L, et al. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol Oncol 1997; 65:94-101.
12. Alvarez RD, Meredith RF, Partridge EE, Kilgore LC, Khazaeli MB, Austin JM, et al. Enhancement of intraperitoneal 177Lu-CC49 radioimmunotherapy with adjuvant interferon and taxol [abstract]. Gynecol Oncol 1998; 68:108.
13. Juweid M, Swayne LC, Sharkey RM, Dunn R, Rubin AD, Herskovic T, • Goldenberg DM. Prospects of radioimmunotherapy in epithelial ovarian cancer: results with iodine-131-labeled murine and humanized MN-14 anticarcinoembryonic antigen monoclonal antibodies Gynecol Oncol 1997; 67:259-271. This study reports the use of an intravenous radiolabeled anti-carcinoembryonic antigen antibody that resulted in good targeting and anti-tumor response.
14. Borchardt PE, Quadri SM, Freedman RS, Vriesendorp HM. Indium-111-and yttrium-90-labeled human monoclonal immunoglobulin M targeting of human ovarian cancer in mice. J Nucl Med 1998; 39:476-484.
15. Horak E, Hartmann F, Garmestani K, Wu C, Brechbiel M, Gansow OA, et al. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1. J Nucl Med 1997; 38:1944-1950.
16. Luiten RM, Warnaar SO, Sanborn D, Lamers CH, Bolhuis RL, Litvinov SV, et al. Chimeric bispecific OC/TR monoclonal antibody mediates lysis of tumor cells expressing the folate-binding protein (MOv18) and displays decreased immunogenicity in patients. J Immunother 1997; 20:496-504.
17. Omelyanenko V, Gentry C, Kopeckova P, Kopecek J. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int J Cancer 1998, 75:600-608.
18. Hasan T, Duska LR, Miller J, Hamblin M. Photodynamic therapy with a photoimmunoconjugate in combination with cisplatinum administration for the treatment of advanced epithelial ovarian cancer [abstract] Proc ASCO 1998; 17:359a.
19. Rancourt C, Rogers BE, Sosnowski BA, Wang M, Piche A, Pierce GF, et al. Basic FGF2- enhancement of a adenovirus mediated delivery of the herpes simplex virus-thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998, 4:2455-2461.
20. Rosenfeld ME, Rogers BE, Khazaeli MB, Mikheeva G, Raben D, Mayo MS, et al. Adenoviral-mediated delivery of gastrin-releasing peptide receptor results in specific tumor localization of a bombesin analogue in vivo. Clin Cancer Res 1997; 3:1187-1194.
21. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin-2-activated autologous human peripheral blood lymphocytes. J Exp Med 1982; 155:1823-1841.
22. Edwards RP, Gooding W, Colonello K, Price FV, Kelley JL, Jacob HE, et al. Outpatient infusion of intraperitoneal interleukin-2 (ip IL-2) is safe and active for persistent ovarian cancer after taxol and platinum [abstract]. Gynecol Oncol 1998, 68:111.
23. Bernsen MR, Van Der Velden AW, Everse LA, Dullins HF, Den Otter W, Heintz AP. Interleukin-2: hope in cases of cisplatin-resistant tumours. Cancer Immunol Immunother 1998; 46:41-47.
24. Berchuck A, Lyerly H. A phase I study of autologous human interleukin-2 (IL-2) gene modified tumor cells in patients with refractory metastatic ovarian cancer. Human gene transfer protocols, Office of Recombinant DNA Activities. Bethesda, Maryland. National Institute of Health, 1995.
25. Berek JS, Stonebraker B, Lentz SS, Adelson MD, DeGeest K, Moore D. Intraperitoneal alpha-mterferon in residual ovarian carcinoma: a phase II gynecologic oncology group study [abstract]. Proc ASCO 1998; 17:358a.
26. Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, et al. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Res 1990; 50:6302-6310.
27. Boente MD, Bookman M, Bast RC. Immunology and immunotherapy. In: Hoskins WJ, Perez CA, Young RC (editors). Principles and practices of gynecologic oncology 2nd Edition.. Philadelphia, USA: Lippincott-Raven; 1997 pp. 170-171.
28. Canevari S, Stoter G, Arienti F, Bolis G, Colnaghi MI, DiRe M, et al. Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. J Natl Cancer Inst 1995; 87:1463-1469.
29. Lamers CH, Bolhuis RL, Warnaar SO, Stoter G, Gratama JW. Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re-targeted by a bi-specific monoclonal antibody. Int J Cancer 1997; 73:211-219.
30. Han X, Papadopoulos AJ, Ruparelia V, Devaja O, Raju KS. Tumor lymphocytes in patients with advanced ovarian cancer: changes during in vitro culture and implications for immunotherapy. Gynecol Oncol 1997; 65:391-398.
31. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 1995; 55.1463-1469.
32. Wang G, Chopra RK, Royal RE, Yang JC, Rosenberg SA, Hwu P. A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen. Nat Med 1998; 4:168-172.
33. Gurski KJ, Steller MA. Progress and prospects in vaccine therapy for • gynecologic cancer Oncology 1997; 11:1-10. A good review of research being done in gynecologic cancer vaccine therapy.
34. Freedman RS, Kudelka AP, Verschraegen CF, Edwards CL, Tomasovic B, Kaplan A, et al. Therapeutic anti-cancer vaccine: a randomized double blind dose comparison study of sialyl TN-KLH with Detox-BSE adjuvant for specific immunotherapy of ovarian cancer (oc) [abstract] Proc ASCO 1998; 17:365a.
35. Dunton CJ, Berd D, Carbon Jr JA, Bloome E, Neufeld J. DNP-modified autologous tumor vaccine to ovarian cancer [abstract]. Gynecol Oncol 1998, 68:111
36. Robinson W, Adams J, Marrogi A, Freemen S Vaccine therapy for ovarian cancer using herpes simplex virus-thymidine kinase suicide gene transfer technique: a phase I trial [abstract]. Gynecol Oncol 1998; 68:88.
37. Dorigo O, Berek JS Gene therapy for ovarian cancer: development of novel treatment strategies. Int J Gynecol Cancer 1997; 7:1-13.
38. Hui KM, Ang PT, Huang L, Tay SK. Phase I study of immunotherapy of cutaneous metastases of human carcinoma using allogeneic and xenogeneic MHC DNA-liposome complexes. Gene Therapy 1997; 4:783-790.